WALTHAM, Mass.--(BUSINESS WIRE)--April 2, 2007--PerkinElmer, Inc.
(NYSE: PKI), a global technology leader in Health Sciences and
Photonics, today announced that it has acquired Improvision Ltd. in a
cash transaction. Based in Coventry, United Kingdom, Improvision is a
leading provider of cellular imaging software and integrated hardware
solutions used in life sciences research. The company had revenue of
approximately GBP 6 million (BPS) in 2006.

A major challenge facing cell biologists and researchers today is
the efficient management of the abundance of data derived from high
content screening (HCS) and advanced confocal microscopy. The addition
of Improvision's robust 3D imaging and analysis software to
PerkinElmer's advanced HCS systems will provide customers with an
unmatched range of powerful, easy-to-use imaging solutions for
analyzing cellular events - from real-time imaging of live cells to
rapid high content screening of multiple samples.

"This acquisition strengthens our leading capability in the
fast-growing field of advanced cellular sciences," said Gregory L.
Summe, chairman and chief executive officer, PerkinElmer, Inc.
"PerkinElmer now provides pharmaceutical and academic researchers with
a single source for imaging and analysis solutions that will help
increase their understanding of disease mechanisms at the cellular
level, potentially speeding the development of new therapies for
conditions such as Alzheimer's, Parkinson's, diabetes and cancer."

Improvision's flagship offering is Volocity(R), a
high-performance, high-throughput 3D and 4D imaging software solution
that allows users to capture, visualize and analyze images of dynamic
cell-based processes, as well as integrated software and hardware
solutions for the control and analysis of microscopy systems. Volocity
complements PerkinElmer's UltraVIEW(R) Live Cell Imaging system, which
captures high-speed, high-resolution, multi-dimensional images of live
biological samples including cultured cells, tissues and embryos.
Additionally, Improvision provides integrated software and hardware
solutions for microscopy systems control and data analysis.

This announcement also builds upon PerkinElmer's recent
acquisition of Evotec Technologies, a leading provider of
high-performance cellular screening systems. PerkinElmer now offers
Evotec Technologies' Opera(TM) High Content Screening platform, a
premier tool for high content analysis that combines the precision of
confocal microscopy with the throughput required for primary and
secondary screening. The product portfolios of Improvision and Evotec
Technologies will be integrated and fully supported by PerkinElmer's
highly regarded sales and service organization.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements relating to estimates and
projections of future earnings per share and revenue growth and other
financial results, developments relating to our customers and
end-markets, and plans concerning business development opportunities.
Words such as "believes," "intends," "anticipates," "plans,"
"expects," "projects," "forecasts," "will" and similar expressions,
and references to guidance, are intended to identify forward-looking
statements. Such statements are based on management's current
assumptions and expectations and no assurances can be given that our
assumptions or expectations will prove to be correct. A number of
important risk factors could cause actual results to differ materially
from the results described, implied or projected in any
forward-looking statements. These factors include, without limitation:
(1) our failure to introduce new products in a timely manner; (2) our
ability to execute acquisitions and license technologies, or to
successfully integrate acquired businesses and licensed technologies
into our existing business or to make them profitable; (3) our failure
to protect adequately our intellectual property; (4) the loss of any
of our licenses or licensed rights; (5) our ability to compete
effectively; (6) fluctuation in our quarterly operating results and
our ability to adjust our operations to address unexpected changes;
(7) our ability to produce an adequate quantity of products to meet
our customers' demands; (8) our failure to maintain compliance with
applicable government regulations; (9) regulatory changes; (10)
economic, political and other risks associated with foreign
operations; (11) our ability to retain key personnel; (12)
restrictions in our credit agreement; (13) our ability to realize the
full value of our intangible assets; and (14) other factors which we
describe under the caption "Risk Factors" in our most recent annual
report on Form 10-K and in our most recent quarterly report on Form
10-Q and in our other filings with the Securities and Exchange
Commission. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and
innovation in Health Sciences and Photonics markets to improve the
quality of life. The Company reported revenues of $1.55 billion in
2006, has 8,500 employees serving customers in more than 125
countries, and is a component of the S&P 500 Index. Additional
information is available through www.perkinelmer.com or
1-877-PKI-NYSE.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding PerkinElmer, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.